Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

Short Communication - (2024)Volume 14, Issue 5

In Silico Molecular Docking Studies of Plumbago zeylanica L. against Androgen Receptor in Prostate Cancer

Siva Lakshmi S*, A Aishwarya, T Monika, H Vetha Merlin Kumari, T Lakshmi Kantham and R Meenakumari
 
*Correspondence: Siva Lakshmi S, Department of Medicine, National Institute of Siddha, Tamil Nadu, India, Email:

Author info »

Abstract

Introduction: In Siddha medicine, a number of herbs are mentioned as possible cancer therapies, both alone and in combination. Such one of the best herb mention in siddha literature is VenKodiveli/ Ven chithramoolam. (PlumbagozeylanicaL.), which is an extremely powerful herb with wide distribution, and also component of many Siddha drugs Like Chitramoola kuligai, chithramoola thylam, etc. In that chithramoolakuligai is specially indicated for Yoni putru (Vaginal cancer), lingaputru (Penile cancer, Prostate cancer), Vippuruthi (All types of cancers). The objective of this study is performing in silico computational analyses of phyto constituents in extracts of the root of Plumbago zeylanica against antrogen receptor for prostate cancer.

Methodology: Docking calculations were carried out for retrieved phytocomponents of Plumbago zeylanica against the target Androgen receptor. Essential hydrogen atoms, Kollman united atom type charges, and solvation parameters were added with the aid of Auto Dock tools.

Observation and inference: Total of 5 bioactive lead compounds were retrieved from the herbal ingredients. From reported data of the herb, the phytochemicals such asLupeol and Stigmasterol reveals maximum of 5 interactions followed by which the compounds such as Plumbagin, Oleic Acid andβ-Asarone reveals maximum of 4 interactions with the core active amino acid residues present on the target androgen receptor.

Conclusion: Based on the results of the computational analysis it was concluded that the bio-active compound’s like Lupeol and Stigmasterol, Plumbagin, Oleic Acidandβ-Asaronepresent in the herbal ingredients possess significant binding affinity towards androgen receptor thereby it may greatly inhibits progression of prostate cancer. Further clinical trials would be beneficial in determining whether this herb is an effective therapy for prostate cancer.

Keywords

Plumbagozeylanica L.; Prostate cancer

Introduction

Cancer is a serious global health concern.It is estimated that 1.46 million cases of cancer occurred in India in 2022, and by 2025, that number is expected to climb to 1.57 million [1]. According to studies, prostate cancer is the fifth most prevalent disease overall and the second most common cancer in men diagnosed globally [2]. Elderly people are predominantly affected by prostate cancer. It ranks as the sixth most common cause of cancer-related deaths among men. Because of the advantages and significance of traditional medicine, the World Health Organisation has designated integrative oncology as one of the main goals of cancer therapy.

Objective

Binding of phyto components with the core amino acids (Leu 873, Gly 708, Arg 752, Met 745, Gln 711 and Met 749) of the target by forming hydrogen bond will hinder the function of the Human androgen receptorwith PDB(Name of the Target) –1E3G(Androgen receptor). The target androgen receptor highly involved in initiation and progression of prostate cancer by contributing to proliferation and differentiation of prostate epithelial cells during development of androgen dependent Prostate Cancer. Thereby phytocomponents which occupies the active amino acids on the androgen receptors will hinder its function and may act as a potential therapeutic agent for management of prostate cancer (Figure 1).

Clinical-Trials-androgen

Figure 1: 3D- structure of androgen receptor (PDB)-1E3G (receptor structure).

Crystalline structure of the target enzyme Androgen receptor (PDB)-1E3G was retrieved from protein data bank and protein clean-up process was done and essential missing hydrogen atom were being added. Different orientation of the lead molecules with respect to the target protein was evaluated by Autodock program and the best dock pose was selected based on the interaction study analysis.

Methodology

Docking calculations were carried out for retrieved phytocomponentsagainst the target Androgen receptor. Essential hydrogen atoms, Kollman united atom type charges, and solvation parameters were added with the aid of AutoDock tools [3-5]. Affinity (grid) maps of ×× Å grid points and 0.375 Å spacing were generated using the Autogrid program [3-5]. AutoDock parameter set- and distance-dependent dielectric functions were used in the calculation of the van der Waals and the electrostatic terms, respectively. Docking simulations were performed using the Lamarckian Genetic Algorithm (LGA) and the Solis and Wets local search method. Initial position, orientation, and torsions of the ligand molecules were set randomly. All rotatable torsions were released during docking. Each docking experiment was derived from 2 different runs that were set to terminate after a maximum of 250000 energy evaluations. The population size was set to 150. During the search, a translational step of 0.2 Å, and quaternion and torsion steps of 5 were applied (Figure 2, Tables 1-3).

Compound Molar weight g/mol Molecular formula H bond donor H bond acceptor Rotatable bonds
Plumbagin 188.182 g/mol C11H8O3 1 3 0
Oleic Acid 282.5 g/mol C18H34O2 1 2 15
β-Asarone 208.25 g/mol C12H16O3 0 3 4
Lupeol 426.7 g/mol   1 1 1
    C30H50O      
Stigmasterol 412.7 g/mol C29H48O 1 1 5

Table 1: Ligand properties of the compounds selected for docking analysis.

Compound Est. free energy of binding Est. inhibition constant, Ki Electrostatic energy Total intermolec. energy Interact. surface
Plumbagin -6.51 kcal/mol 17.04 uM -0.13 kcal/mol -6.80 kcal/mol 371.224
Oleic Acid -4.50 kcal/mol 506.48 uM -0.20 kcal/mol -4.79 kcal/mol 300.18
β-Asarone -5.22 kcal/mol 149.17 uM -0.09 kcal/mol -6.45 kcal/mol 465.787
Lupeol -2.51 kcal/mol 14.52 mM -0.06 kcal/mol -4.78 kcal/mol 665.339
Stigmasterol -3.25 kcal/mol 4.12 mM +0.02 kcal/mol -5.46 kcal/mol 654.167

Table 2: Summary of the molecular docking studies of compounds against androgen receptor (PDB)-1E3G.

Compounds Interactions Amino acid residues
Plumbagin 4 704 707 711 745 746 749 752 764                  
    LEU LEU GLN MET VAL MET ARG PHE                  
Oleic Acid 4 704 707 711 745 746 749 764 787 873                
    LEU LEU GLN MET VAL MET PHE MET LEU                
β-Asarone 4 704 705 707 711 745 746 749 764 787 873              
    LEU ASN LEU GLN MET VAL MET PHE MET LEU              
Lupeol 5 704 705 707 711 742 745 749 752 764 780 873 876 877 880 891 895  
    LEU ASN LEU GLN MET MET MET ARG PHE MET LEU PHE THR LEU PHE MET  
Stigmasterol 5 701 704 705 707 711 742 745 746 749 752 764 780 873 876 877 880 891
    LEU LEU ASN LEU GLN MET MET VAL MET ARG PHE MET LEU PHE THR LEU PHE

Table 3: Amino acid residue interaction of lead against androgen receptor (PDB)-1E3G.

Clinical-Trials-ligands

Figure 2: 2D and 3D structure of selected ligands. Note: A: Plumbagin; B: Oleic Acid; C: Lupeol; D: β-Asarone; E: Stigmasterol.

Results and Discussion

Total of 5 bioactive lead compounds were retrieved from the herbal ingredients. From reported data of the herb, the phytochemicals such asLupeol and Stigmasterolreveals maximum of 5 interactions followed by which the compounds such as Plumbagin, Oleic Acid andβ-Asarone reveals maximum of 4 interactionswith the core active amino acid residues present on the target androgen receptor.

Conclusion

Based on the results of the computational analysis it was concluded that the bio-active compound’s present in Plumbago zeylanica L. like Lupeol and Stigmasterol, Plumbagin, Oleic Acidandβ- Asaronepossess significant binding affinity towards androgen receptor thereby it may greatly inhibits progression of prostate cancer by limiting the proliferation and differentiation of prostate epithelial cells during development of prostate Cancer. Thereby phytocomponents which occupies the active amino acids on the androgen receptors will hinder its function and may act as a potential therapeutic agent for management of prostate cancer.

Funding Declaration

No funding.

Competing Interests

No competing interests.

References

Author Info

Siva Lakshmi S*, A Aishwarya, T Monika, H Vetha Merlin Kumari, T Lakshmi Kantham and R Meenakumari
 
Department of Medicine, National Institute of Siddha, Tamil Nadu, India
 

Citation: Lakshmi SS, Aishwarya A, Monika T, Kumari HVM, Kantham TL, Meenakumari R (2024) In Silico Molecular Docking Studies of Plumbago zeylanica L. against Androgen Receptor in Prostate Cancer. J Clin Trials. 14:569.

Received: 08-Jul-2024, Manuscript No. JCTR-24-31929; Editor assigned: 10-Jul-2024, Pre QC No. JCTR-24-31929(PQ); Reviewed: 24-Jul-2024, QC No. JCTR-24-31929; Revised: 31-Jul-2024, Manuscript No. JCTR-24-31929(R); Published: 07-Aug-2024 , DOI: 10.35248/2167-0870.24.14.569

Copyright: © 2024 Lakshmi SS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top